Physician profile
Garima Arora
NPI 1497043137
$5,001.62
in general payments reported to CMS, 2019-2025
33 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $174 · 2021: $678 · 2022: $593 · 2023: $922 · 2024: $1,024 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.50 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $485.75 | 2019-2023 | Invega Sustenna |
| Lundbeck LLC | $480.08 | 2019-2024 | Vyepti |
| Sunovion Pharmaceuticals INC. | $477.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $453.98 | 2019-2025 | Trintellix, Hyqvia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.05 | 2021-2025 | Caplyta |
| Ucb, INC. | $367.42 | 2023-2025 | Rystiggo, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $233.24 | 2023-2025 | Nuplazid |
| Abbvie INC. | $218.10 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $208.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $182.62 | 2021-2023 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $172.27 | 2022-2024 | |
| Shire North American Group INC | $144.93 | 2019 | |
| Neurocrine Biosciences, INC. | $143.62 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $133.32 | 2020-2024 | |
| Biogen, INC. | $125.85 | 2023-2025 | Vumerity, Tysabri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $103.42 | 2022-2023 | Azstarys |
| Lilly USA, LLC | $85.59 | 2023-2025 | Amyvid, Kisunla |
| Abbott Laboratories | $64.95 | 2024-2025 | Proclaim, Mitraclip |
| Azurity Pharmaceuticals, INC. | $55.26 | 2024-2025 | Horizant |
| Boston Scientific Corporation | $55.21 | 2023 | |
| Merz Pharmaceuticals, LLC | $54.50 | 2023-2024 | Xeomin |
| Novartis Pharmaceuticals Corporation | $51.92 | 2024-2025 | |
| Emd Serono, INC. | $49.55 | 2023 | Mavenclad |
| Genentech USA, INC. | $39.97 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Livanova USA, INC. | $38.77 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $33.05 | 2019 | |
| Averitas Pharma INC. | $27.99 | 2023 | Qutenza |
| Tg Therapeutics, INC. | $24.72 | 2024 | |
| Vanda Pharmaceuticals INC. | $23.99 | 2019 | |
| Grifols USA, LLC | $23.16 | 2023 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $22.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.54 | 2023 | |
| Owp Pharmaceuticals, INC. | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garima Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.